Published in J Am Coll Cardiol on April 10, 2013
Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res (2013) 3.56
Growth properties of cardiac stem cells are a novel biomarker of patients' outcome after coronary bypass surgery. Circulation (2013) 2.19
Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials. Circ Res (2015) 1.80
Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res (2015) 1.57
Evaluation of Changes in Morphology and Function of Human Induced Pluripotent Stem Cell Derived Cardiomyocytes (HiPSC-CMs) Cultured on an Aligned-Nanofiber Cardiac Patch. PLoS One (2015) 1.43
The advancing field of cell-based therapy: insights and lessons from clinical trials. J Am Heart Assoc (2013) 1.40
Frequency of discrepancies in retracted clinical trial reports versus unretracted reports: blinded case-control study. BMJ (2015) 1.39
The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE). J Am Coll Cardiol (2013) 1.26
Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network. Circ Res (2014) 1.12
A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J Transl Med (2014) 1.10
Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges. Circ Res (2014) 1.09
The winding road to regenerating the human heart. Cardiovasc Pathol (2015) 1.04
Cardiac regeneration: current therapies-future concepts. J Thorac Dis (2013) 1.04
Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy? Circ Res (2015) 1.03
Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement. J Am Coll Cardiol (2014) 1.02
Breakthroughs in cell therapy for heart disease: focus on cardiosphere-derived cells. Mayo Clin Proc (2014) 1.02
Controlling the structural and functional anisotropy of engineered cardiac tissues. Biofabrication (2014) 0.98
Regenerative heart failure therapy headed for optimization. Eur Heart J (2014) 0.98
Pre-conditioned mesenchymal stem cells: a better way for cell-based therapy. Stem Cell Res Ther (2013) 0.93
Stem cell therapy for heart failure: Ensuring regenerative proficiency. Trends Cardiovasc Med (2016) 0.93
Making it stick: chasing the optimal stem cells for cardiac regeneration. Expert Rev Cardiovasc Ther (2014) 0.91
Stem cell therapy for cardiac dysfunction. Springerplus (2014) 0.90
Multipotent (adult) and pluripotent stem cells for heart regeneration: what are the pros and cons? Stem Cell Res Ther (2013) 0.90
Mesenchymal stem cell therapy for cardiac repair. Curr Treat Options Cardiovasc Med (2014) 0.90
Identification of appropriate reference genes for human mesenchymal cells during expansion and differentiation. PLoS One (2013) 0.88
Optimized delivery system achieves enhanced endomyocardial stem cell retention. Circ Cardiovasc Interv (2013) 0.86
Regenerative Medicine Build-Out. Stem Cells Transl Med (2015) 0.85
Proof of principle: quality control of therapeutic cell preparations using senescence-associated DNA-methylation changes. BMC Res Notes (2014) 0.85
Recent advances in the diagnosis and treatment of acute myocardial infarction. World J Cardiol (2015) 0.85
More Than Tiny Sacks: Stem Cell Exosomes as Cell-Free Modality for Cardiac Repair. Circ Res (2016) 0.84
Cell Therapy in Ischemic Heart Disease: Interventions That Modulate Cardiac Regeneration. Stem Cells Int (2016) 0.84
Reply: The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE). J Am Coll Cardiol (2013) 0.84
Doubts over heart stem-cell therapy. Nature (2014) 0.83
Molecular and cellular basis of viable dysfunctional myocardium. Circ Heart Fail (2014) 0.83
The Evolution of the Stem Cell Theory for Heart Failure. EBioMedicine (2015) 0.82
Stem cells: bone-marrow-derived cells and heart failure--the debate goes on. Nat Rev Cardiol (2013) 0.82
Moving beyond surrogate endpoints in cell therapy trials for heart disease. Stem Cells Transl Med (2013) 0.82
How to Improve the Survival of Transplanted Mesenchymal Stem Cell in Ischemic Heart? Stem Cells Int (2015) 0.81
Cardiopoietry in motion: primed mesenchymal stem cells for ischemic cardiomyopathy. J Am Coll Cardiol (2013) 0.81
Human cardiospheres as a source of multipotent stem and progenitor cells. Stem Cells Int (2013) 0.80
The potential of stem cells in the treatment of cardiovascular diseases. Stem Cell Rev (2013) 0.80
Bone marrow-derived mesenchymal stem cells for the treatment of heart failure. Heart Fail Rev (2015) 0.80
Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. Eur J Heart Fail (2015) 0.80
Blood vessel repair and regeneration in the ischaemic heart. Open Heart (2014) 0.79
Efficacy and safety of bone marrow cell transplantation for chronic ischemic heart disease: a meta-analysis. Med Sci Monit (2014) 0.79
Finding and tracing human MSC in 3D microenvironments with the photoconvertible protein Dendra2. Sci Rep (2015) 0.79
Cardiac Regenerative Medicine: The Potential of a New Generation of Stem Cells. Transfus Med Hemother (2016) 0.79
Clinical trials of bone marrow derived cells for ischemic heart failure. Time to move on? TIME, SWISS-AMI, CELLWAVE, POSEIDON and C-CURE. Glob Cardiol Sci Pract (2013) 0.78
Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J (2016) 0.78
Cardiac tissue engineering and regeneration using cell-based therapy. Stem Cells Cloning (2015) 0.78
Cell surface glycoengineering improves selectin-mediated adhesion of mesenchymal stem cells (MSCs) and cardiosphere-derived cells (CDCs): Pilot validation in porcine ischemia-reperfusion model. Biomaterials (2015) 0.78
Stem cells for the treatment of heart failure. Philos Trans R Soc Lond B Biol Sci (2015) 0.78
Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia. Stem Cell Res Ther (2016) 0.77
Cortical bone-derived stem cells: a novel class of cells for myocardial protection. Circ Res (2013) 0.77
Translational research of adult stem cell therapy. World J Cardiol (2015) 0.77
Regenerative principles enrich cardiac rehabilitation practice. Am J Phys Med Rehabil (2014) 0.77
"Second-generation" stem cells for cardiac repair. World J Stem Cells (2015) 0.77
Myocyte renewal and therapeutic myocardial regeneration using various progenitor cells. Heart Fail Rev (2014) 0.77
Stem cells and diabetic cardiomyopathy: from pathology to therapy. Heart Fail Rev (2016) 0.77
Stem cell-derived exosomes as a therapeutic tool for cardiovascular disease. World J Stem Cells (2016) 0.77
New strategies for improving stem cell therapy in ischemic heart disease. Heart Fail Rev (2016) 0.77
Clinical development plan for regenerative therapy in heart failure. Eur J Heart Fail (2016) 0.76
Intracoronary Delivery of Human Mesenchymal/Stromal Stem Cells: Insights from Coronary Microcirculation Invasive Assessment in a Swine Model. PLoS One (2015) 0.76
Treatment with hESC-Derived Myocardial Precursors Improves Cardiac Function after a Myocardial Infarction. PLoS One (2015) 0.76
Endpoints in stem cell trials in ischemic heart failure. Stem Cell Res Ther (2015) 0.76
Stem cell mechanisms during left ventricular remodeling post-myocardial infarction: Repair and regeneration. World J Cardiol (2014) 0.76
In Vivo Tracking of Systemically Administered Allogeneic Bone Marrow Mesenchymal Stem Cells in Normal Rats through Bioluminescence Imaging. Stem Cells Int (2016) 0.76
Neural Crest Stem Cells Can Differentiate to a Cardiomyogenic Lineage with an Ability to Contract in Response to Pulsed Infrared Stimulation. Tissue Eng Part C Methods (2016) 0.75
Functional Effects of Delivering Human Mesenchymal Stem Cell-Seeded Biological Sutures to an Infarcted Heart. Biores Open Access (2016) 0.75
MiR-211/STAT5A Signaling Modulates Migration of Mesenchymal Stem Cells to Improve its Therapeutic Efficacy. Stem Cells (2016) 0.75
The role of coronary microvascular disorder in congestive heart failure. Am J Physiol Heart Circ Physiol (2015) 0.75
Impact of umbilical cord blood-derived mesenchymal stem cells on cardiovascular research. Biomed Res Int (2015) 0.75
Prion Protein and Stage Specific Embryo Antigen 1 as Selection Markers to Enrich the Fraction of Murine Embryonic Stem Cell-Derived Cardiomyocytes. Yonago Acta Med (2016) 0.75
Cellular Therapy for Heart Failure. Curr Cardiol Rev (2016) 0.75
Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients. J Immunol Res (2015) 0.75
Progenitor Hematopoietic Cells Implantation Improves Functional Capacity of End Stage Coronary Artery Disease Patients with Advanced Heart Failure. Cardiol Res Pract (2016) 0.75
Combined biophysical and soluble factor modulation induces cardiomyocyte differentiation from human muscle derived stem cells. Sci Rep (2014) 0.75
Redirecting stem cell therapy. Natl Med J India (2014) 0.75
Activation of Notch1 signalling promotes multi-lineage differentiation of c-Kit(POS)/NKX2.5(POS) bone marrow stem cells: implication in stem cell translational medicine. Stem Cell Res Ther (2015) 0.75
Dynamic Tracking Human Mesenchymal Stem Cells Tropism following Smoke Inhalation Injury in NOD/SCID Mice. Stem Cells Int (2016) 0.75
Vascular stem cells-potential for clinical application. Br Med Bull (2016) 0.75
Human iPS Cell-Derived Cardiac Tissue Sheets: a Platform for Cardiac Regeneration. Curr Treat Options Cardiovasc Med (2016) 0.75
Regenerative rehabilitation: a new future? Am J Phys Med Rehabil (2014) 0.75
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J (2017) 0.75
Novel molecular targets for coronary angiogenesis and ischemic heart disease. Coron Artery Dis (2017) 0.75
Left ventricular ejection fraction as therapeutic target: is it the ideal marker? Heart Fail Rev (2017) 0.75
Intramyocardial Injection of Stem Cells in Pig Myocardial Infarction Model: The First Trial in Korea. J Korean Med Sci (2017) 0.75
Evaluation of the use of unipolar voltage amplitudes for detection of myocardial scar assessed by cardiac magnetic resonance imaging in heart failure patients. PLoS One (2017) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Universal definition of myocardial infarction. Circulation (2007) 11.69
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol (2011) 5.46
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med (2015) 5.36
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03
Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol (2007) 5.02
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 4.68
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Relationship between noninvasive coronary angiography with multi-slice computed tomography and myocardial perfusion imaging. J Am Coll Cardiol (2006) 4.37
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 4.24
Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab (2011) 4.15
Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14
The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J (2006) 4.10
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet (2006) 3.15
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol (2007) 3.05
Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation (2009) 2.93
ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat Genet (2004) 2.85
DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J (2004) 2.85
Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol (2008) 2.81
Phosphotransfer networks and cellular energetics. J Exp Biol (2003) 2.79
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J (2005) 2.78
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol (2008) 2.68
Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J (2004) 2.68
Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (2009) 2.68
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation (2008) 2.62
Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol (2006) 2.61
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci U S A (2002) 2.60
Stem cell differentiation requires a paracrine pathway in the heart. FASEB J (2002) 2.55
Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol (2004) 2.39
Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell (2012) 2.36
Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation (2005) 2.35
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J (2012) 2.30
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice. J Cell Biol (2006) 2.24
Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiovasc Med (2007) 2.21
Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation. Catheter Cardiovasc Interv (2010) 2.15
Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis. Eur Heart J (2008) 2.13
Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease. JACC Cardiovasc Interv (2010) 2.08
Cardiac system bioenergetics: metabolic basis of the Frank-Starling law. J Physiol (2006) 2.06
Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv (2010) 2.06
Cardiac KATP channels in health and disease. J Mol Cell Cardiol (2005) 2.04
Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography. Am Heart J (2006) 2.02
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet (2012) 2.00
Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography. Circulation (2004) 2.00
Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol (2008) 1.99
Diagnostic performance of multidetector CT angiography for assessment of coronary artery disease: meta-analysis. Radiology (2007) 1.97
Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med (2007) 1.97